Microcap Ledger Artelo Biosciences, Inc. $ARTL
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Solana Beach, CA
- Fiscal year end
- December 31
- Shares outstanding
- 4,595,068 [10-Q/A 2026-08-20]
What the company doesAI summary of filing
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system. The company has three main product candidates: ART27.13, a dual cannabinoid receptor agonist in Phase 1b/2a trials for cancer-related anorexia; ART26.12, a FABP5 inhibitor in Phase 1 trials for chemotherapy-induced peripheral neuropathy with potential applications in cancer, pain, dermatologic conditions, and anxiety disorders; and ART12.11, a proprietary CBD cocrystal composition in preclinical development for anxiety and other indications. The company generates no product revenue and is funded through licensing agreements with milestone and royalty payments. [10-K 2026-02-24]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$5.38M | −$6.22M | $4.20M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | −$12.88M | −$8.52M | $600.0K | [8-K 2026-03-17] |
| FY ended Dec 2024 | — | −$9.83M | −$8.35M | $2.34M | [8-K 2026-03-17] |
- Quarterly cash burn
- −$3.11M
- Cash runway Estimate
- ~4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 3,227,700 | [10-Q 2024-11-12] |
| 2025-02-27 | 3,281,032 | [10-K 2025-03-03] |
| 2025-05-12 | 3,281,032 | [10-Q 2025-05-13] |
| 2025-08-12 | 1,321,552 | [10-Q 2025-08-13] |
| 2025-11-10 | 2,018,746 | [10-Q 2025-11-12] |
| 2026-02-20 | 2,124,772 | [10-K 2026-02-24] |
| 2026-05-13 | 2,333,540 | [10-Q 2026-05-14] |
| 2026-08-11 | 4,595,068 | [10-Q/A 2026-08-20] |
- Shelf registration
- S-3 filed 2026-05-04; declared effective 2026-05-19 [S-3 2026-05-04]
Listing status
Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-01-16. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-01-16 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-16] |
| 2025-11-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-11-25] |
| 2025-05-23 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-23] |
| 2025-04-29 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Other events |
| 2026-08-27 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Regulation FD disclosure |
| 2026-08-20 | 10-Q/A | Amended report |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-07-17 | 8-K | Shareholder vote results |
| 2026-06-05 | DEF 14A | Proxy statement |
| 2026-05-27 | 8-K | Material agreement entered; Other events |
| 2026-05-26 | PRE 14A | Proxy statement |
| 2026-05-26 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-18 | 424B5 | Prospectus or prospectus supplement |
Alerts for $ARTL
Email me when Artelo Biosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.